Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021; 23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
COVID-19 underscores historical precedent for fear-driven responses that disregard autonomy among persons with low income who are also persons of color.
AMA J Ethics. 2021; 23(11):E840-846. doi:
10.1001/amajethics.2021.840.
Felix Gonzalez-Torres' and Gregg Bordowitz’s works express their experiences of living through a pandemic and subsequent social change and draw out key human rights themes.
AMA J Ethics. 2020; 22(9):E821-829. doi:
10.1001/amajethics.2020.821.
In the 1910s, the American Medical Association fought quackery promoted in pamphlets for drugs and treatments for everything from teething to epilepsy.
AMA J Ethics. 2018; 20(11):E1082-1093. doi:
10.1001/amajethics.2018.1082.
Nanoscale products pose ethical, legal, and policy challenges to governing the use of products that integrate multiple mechanisms of therapeutic action.
AMA J Ethics. 2019; 21(4):E347-355. doi:
10.1001/amajethics.2019.347.